Back to results
US 2017/0319689 A1Published application
Methods, Regimens, Combinations & Antagonists
AssigneeKymab Limited
InventorsVolker GERMASCHEWSKI, Igor Theurl, Martin Yateman, Jasper Clube, Steve Arkinstall
Life of this patent
Estimating the term…
Abstract
The invention relates to treating or preventing anaemia in a subject, such as a mammal or human. In particular, the invention addresses moderate to severe anaemia. Additionally, the invention provides means for sparing administration of erythropoiesis stimulating agents (ESAs) to subjects.
Claims30
A method of treating anaemia in a subject, the method comprising
- (a) on an initial day (D0) administering to the subject an anti-BMP6 antibody or antigen-binding fragment thereof;
- and
- (b) in a treatment period of at least 3 consecutive weeks, said period starting on D0, administering a plurality of doses of an erythropoietin stimulating agent (ESA) wherein
- (i) the haemoglobin (Hb) concentration in said subject during said treatment period is no lower than 100% of a baseline Hb concentration on D0 prior to anti-BMP6 antibody or antigen-binding fragment administration, and during said treatment period Hb concentration reaches at least 120% of baseline;
- and/or
- (ii) the Hb concentration in said subject is increased over baseline by at least 1 g/dl for the duration of the treatment period.
3 more elements
Dependencies are inferred from the claim text.